Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Endourol ; 36(3): 410-416, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-34806408

RESUMO

Purpose: The aim of this study is to conduct a prospective, controlled single-center study to determine the prevalence and types of ureteral stent symptoms in kidney transplant (KTx) recipients and compare them with nontransplant subjects. Materials and Methods: From December 2012 to June 2019, a total of 102 patients having undergone a KTx and Double-J stent (DJS) placement and 88 patients having undergone endourological lithotripsy and DJS placement were enrolled. The Ureteral Stent Symptom Questionnaire (USSQ) was administered to patients with a median of 25 (KTx) and 31 (urolithiasis) days after stent placement. USSQ scores were used to compare symptoms between the two groups. Results: Of the 190 patients enrolled, 88 belonged to the lithotripsy group (control group) and 102 to the KTx recipients' group. Mean score for urinary symptoms was 21.42 for KTx patients vs 27.53 for control patients with statistical significance (p < 0.001, CI -7.792 to -4.433). The visual analog scale, overall bother, pain at voiding, flank pain at voiding, and frequency of painkiller use scores were significantly higher for control patients than for KTx patients (p = 0.024, <0.001, <0.001, <0.001, and 0.014, respectively). Frequency of rest, changes in work duration, work domain score, suspicion of urinary tract infection (UTI), and need for professional assistance scores were significantly lower for KTx patients than the control. There were no significant differences in general health and sexual domains between groups. Conclusions: KTx recipients have significantly fewer urinary symptoms, pain, work-related disturbances, suspected UTIs, and hospitalizations associated with stent placement than urolithiasis patients.


Assuntos
Transplante de Rim , Ureter , Urolitíase , Feminino , Humanos , Transplante de Rim/efeitos adversos , Masculino , Dor/etiologia , Estudos Prospectivos , Stents/efeitos adversos , Inquéritos e Questionários , Ureter/cirurgia
2.
Rev. cientif. cienc. med ; 22(1): 62-67, 2019. ilus
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1098935

RESUMO

Paciente femenino de 14 años, refiere estreñimiento, oligomenorrea y cefalea. Presenta giba dorsal, bocio, acantosis nigricans, genu valgo (deformidad en la alineación de las rodillas), piel seca, índice de Masa Corporal (IMC) 38,5 kg/m² (>Percentil 97), grasa corporal 46,9% (bioimpedancia eléctrica), circunferencia de cintura >Percentil 90, cifras de tensión arterial: 95/60 mmHg (valores normales para edad y sexo). Perfil tiroideo: Hormona Estimulante de Tiroides (TSH) 203,19 μUl/ml, T4 Libre 0,29 ng/dl, anticuerpos anti-tiroperoxidasa (anti TPO) 359,4 Ul/ml. Se diagnosticó Tiroiditis de Hashimoto al detectar hipotiroidismo primario aunado a elevación de anti TPO. Ultrasonido de cuello con incremento de lóbulos tiroideos sin calcificación ni vascularidad. Inició levotiroxina 100 μg/día, a 6 meses de manejo: pérdida ponderal de 5,5 kg, IMC 36,7 kg/m², remisión de síntomas, con mejoría en pruebas de función tiroidea. La paciente refiere ser producto de embarazo complicado con preeclampsia, no recibió lactancia materna, ablactación temprana, sedentaria, con incremento ponderal desde la infancia.


Female patient of 14 years oíd, refers constipation, oligomenorrhea and headache. She has dorsal hump, goiter, acanthosis nigricans, geno valgus (deformity in the alignment of the knees), dry skin, Body Mass Index (BMI) 38,5 kg/m² (> Percentile 97), body fat 46,9% (bioelectrical impedance analysis), waist circumference> Percentile 90, blood pressure levels (95/60 mmHg) in normal values for age and sex. Thyroid profile:TSH 203,19 μUl/ml, FT4 0,29 ng/dl, anti thyroperoxidase antibodies (anti TPO) 359,4 IU / ml. Hashimoto's thyroiditis was diagnosed by detecting primary hypothyroidism coupled with elevation of anti TPO. Ultrasound of the neck with increased thyroid lobes without calcification or vascularity. Started levothyroxine 100 μg / day, 6 months of management: weight loss of 5,5 kg, BMI 36,7 kg/m2, remission of symptoms, with improvement in thyroid function tests. Patient with a history of being a pregnancy product complicated by preeclampsia, did not receive breastfeeding, early ablation, sedentary, with a weight increase since childhood.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...